203 related articles for article (PubMed ID: 32678295)
1. Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow.
Buschhaus JM; Humphries BA; Eckley SS; Robison TH; Cutter AC; Rajendran S; Haley HR; Bevoor AS; Luker KE; Luker GD
Oncogene; 2020 Aug; 39(34):5649-5662. PubMed ID: 32678295
[TBL] [Abstract][Full Text] [Related]
2. A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells.
Möhrmann L; Zowada MK; Strakerjahn H; Siegl C; Kopp-Schneider A; Krunic D; Strunk D; Schneider M; Kriegsmann M; Kriegsmann K; Herbst F; Ball CR; Glimm H; Dieter SM
Int J Cancer; 2020 Jul; 147(2):519-531. PubMed ID: 32077087
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients - results from a large single-centre analysis.
Hartkopf AD; Taran FA; Wallwiener M; Hahn M; Becker S; Solomayer EF; Brucker SY; Fehm TN; Wallwiener D
Eur J Cancer; 2014 Oct; 50(15):2550-9. PubMed ID: 25096167
[TBL] [Abstract][Full Text] [Related]
4. Angiopoietin-2 promotes ER+ breast cancer cell survival in bone marrow niche.
Han HH; Kim BG; Lee JH; Kang S; Kim JE; Cho NH
Endocr Relat Cancer; 2016 Aug; 23(8):609-23. PubMed ID: 27353038
[TBL] [Abstract][Full Text] [Related]
5. Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
Deng G; Krishnakumar S; Powell AA; Zhang H; Mindrinos MN; Telli ML; Davis RW; Jeffrey SS
BMC Cancer; 2014 Jun; 14():456. PubMed ID: 24947048
[TBL] [Abstract][Full Text] [Related]
6. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
8. A Facile, In Vitro 384-Well Plate System to Model Disseminated Tumor Cells in the Bone Marrow Microenvironment.
Buschhaus JM; Luker KE; Luker GD
Methods Mol Biol; 2018; 1686():201-213. PubMed ID: 29030823
[TBL] [Abstract][Full Text] [Related]
9. Modeling selective elimination of quiescent cancer cells from bone marrow.
Cavnar SP; Rickelmann AD; Meguiar KF; Xiao A; Dosch J; Leung BM; Cai Lesher-Perez S; Chitta S; Luker KE; Takayama S; Luker GD
Neoplasia; 2015 Aug; 17(8):625-33. PubMed ID: 26408255
[TBL] [Abstract][Full Text] [Related]
10. Prevention of cancer dormancy by Fbxw7 ablation eradicates disseminated tumor cells.
Shimizu H; Takeishi S; Nakatsumi H; Nakayama KI
JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830867
[TBL] [Abstract][Full Text] [Related]
11. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Yndestad S; Austreid E; Svanberg IR; Knappskog S; Lønning PE; Eikesdal HP
Oncotarget; 2017 Jun; 8(25):41227-41241. PubMed ID: 28476032
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic significance of disseminated tumor cells in the bone marrow of primary, non-metastatic breast cancer patients after a 7-year follow-up.
Hoffmann O; Schroer-Zuendorf IA; Kasimir-Bauer S; Oberhoff C; Kimmig R; Heubner M
Arch Gynecol Obstet; 2015 Nov; 292(5):1117-25. PubMed ID: 25986892
[TBL] [Abstract][Full Text] [Related]
13. Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
Liu S; Meng X; Chen H; Liu W; Miller T; Murph M; Lu Y; Zhang F; Gagea M; Arteaga CL; Mills GB; Meric-Bernstam F; González-Angulo AM
Oncotarget; 2014 Oct; 5(19):9049-64. PubMed ID: 24979294
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin inhibits proliferation of estrogen-receptor-positive breast cancer cells.
Chang SB; Miron P; Miron A; Iglehart JD
J Surg Res; 2007 Mar; 138(1):37-44. PubMed ID: 17109887
[TBL] [Abstract][Full Text] [Related]
15. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
[TBL] [Abstract][Full Text] [Related]
16. Maintenance of S-nitrosothiol homeostasis plays an important role in growth suppression of estrogen receptor-positive breast tumors.
Cañas A; López-Sánchez LM; Valverde-Estepa A; Hernández V; Fuentes E; Muñoz-Castañeda JR; López-Pedrera C; De La Haba-Rodríguez JR; Aranda E; Rodríguez-Ariza A
Breast Cancer Res; 2012 Dec; 14(6):R153. PubMed ID: 23216744
[TBL] [Abstract][Full Text] [Related]
17. Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.
Falck AK; Bendahl PO; Ingvar C; Isola J; Jönsson PE; Lindblom P; Lövgren K; Rennstam K; Fernö M; Rydén L
BMC Cancer; 2012 Sep; 12():403. PubMed ID: 22963449
[TBL] [Abstract][Full Text] [Related]
18. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
[TBL] [Abstract][Full Text] [Related]
19. Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Kasimir-Bauer S; Bittner AK; König L; Reiter K; Keller T; Kimmig R; Hoffmann O
Breast Cancer Res; 2016 Feb; 18(1):20. PubMed ID: 26868521
[TBL] [Abstract][Full Text] [Related]
20. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
